AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24385141 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with antioxidant vitamins and minerals
Number of subjects: 4757
Study 22196768 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of PF-03654746 plus 60 mg of fexofenadine (group 1)
Number of subjects: 20
Study 22196768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of PF-03654746 plus 60 mg of fexofenadine (group 2)
Number of subjects: 20
Study 22196768 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of fexofenadine/120 mg of pseudoephedrine (group 3)
Number of subjects: 20
Study 22196768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 20
Study 20307797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize draw incentive program (up to $400 over 3 months)
Number of subjects: 803
Study 18566198 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA propofol for 5 minutes
Number of subjects: 28
Study 18566198 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA propofol for 20 minutes
Number of subjects: 28
Study 15776773 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac)
Number of subjects: 0
Study 15776773 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac) in combination with oral doxycycline hyclate (Doryx) and adapalene gel (Differin)
Number of subjects: 0
Study 12005454 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid-based lipid emulsion (fish oil, 10%; 200 mL/d)
Number of subjects: 22
Study 12005454 — intervention group
Group type: COMPARATOR
Intervention: n-6 lipid emulsion (soybean oil, 10%; 200 mL/d)
Number of subjects: 22
Study 10404344 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg od
Number of subjects: 124
Study 10404344 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 250 mg od
Number of subjects: 124
Study 10404344 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil 250 mg bd
Number of subjects: 124
Study 7562275 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula (group We)
Number of subjects: 74
Study 7562275 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-derived formula (group AA)
Number of subjects: 74
Study 7562275 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed control infants
Number of subjects: 74
Study 7562275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas (group We and group AA)
Number of subjects: 74
Study 2332608 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of prazepam in liquid drops
Number of subjects: 10
Study 2332608 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of prazepam in tablets
Number of subjects: 10
Study 7266731 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline chloride (2 g QID)
Number of subjects: 10
Study 7266731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31928963 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sitagliptin daily for 3 consecutive cycles
Number of subjects: 38
Study 31928963 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo capsules
Number of subjects: 38
Study 30053213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT)
Number of subjects: 10
Study 30053213 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 10
Study 28595613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia information resource in conjunction with standard participant information sheets
Number of subjects: 0
Study 28595613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia information resource alone
Number of subjects: 0
Study 28595613 — intervention group
Group type: COMPARATOR
Intervention: Standard participant information sheets alone
Number of subjects: 0
Study 28595613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia information resources
Number of subjects: 0
Study 25728152 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel silver-impregnated Foley catheter system
Number of subjects: 95
Study 25728152 — intervention group
Group type: COMPARATOR
Intervention: Control system
Number of subjects: 95
Study 23531689 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise group (AEG)
Number of subjects: 108
Study 23531689 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study 21317776 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 90
Study 21317776 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 90
Study 21317776 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study 18707776 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report psychosocial measures
Number of subjects: 280
Study 18707776 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured clinical interviews
Number of subjects: 280
Study 17006780 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS intervention group (15 h of PECS teaching over 5 weeks)
Number of subjects: 2
Study 17006780 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention control group (no PECS teaching)
Number of subjects: 2
Study 15365580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or desipramine (active treatment) for 8 weeks
Number of subjects: 80
Study 11548133 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week behaviorally based telephone and mail intervention promoting walking for exercise
Number of subjects: 102
Study 11548133 — intervention group
Group type: COMPARATOR
Intervention: Non-behavioral minimal intervention
Number of subjects: 102
Study 10874061 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy guided by electrophysiologic testing
Number of subjects: 1750
Study 10874061 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy
Number of subjects: 1750
Study 10874061 — intervention group
Group type: COMPARATOR
Intervention: Registry patients (no inducible tachyarrhythmias)
Number of subjects: 1750
Study 9175963 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine
Number of subjects: 12
Study 9175963 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 12
Study 1552468 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline periodontal formulation
Number of subjects: 0
Study 1552468 — intervention group
Group type: COMPARATOR
Intervention: Placebo periodontal formulation
Number of subjects: 0
Study 3874932 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate with citrovorum factor rescue (MTX-CF)
Number of subjects: 30
Study 3874932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial cis-diamminedichloroplatinum II (I/A-CDP)
Number of subjects: 30
Study 31226342 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational tweets
Number of subjects: 782
Study 31226342 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational senders
Number of subjects: 782
Study 31226342 — intervention group
Group type: COMPARATOR
Intervention: Personal experience tweets
Number of subjects: 782
Study 31226342 — intervention group
Group type: COMPARATOR
Intervention: Rare personal experience messages
Number of subjects: 782
Study 31226342 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages using organizational senders and factual information
Number of subjects: 782
Study 29356820 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based platform
Number of subjects: 459
Study 29356820 — intervention group
Group type: COMPARATOR
Intervention: Genetic counselor
Number of subjects: 459
Study 26483177 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of omalizumab
Number of subjects: 975
Study 26483177 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of omalizumab
Number of subjects: 975
Study 26483177 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of omalizumab
Number of subjects: 975
Study 26483177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study 24567516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg once weekly (CIL1W) + PFE
Number of subjects: 182
Study 24567516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg twice weekly (CIL2W) + PFE
Number of subjects: 182
Study 24567516 — intervention group
Group type: COMPARATOR
Intervention: PFE alone
Number of subjects: 182
Study 23113436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mission Essential Fitness (MEF) circuit-style training
Number of subjects: 67
Study 23113436 — intervention group
Group type: COMPARATOR
Intervention: Army Physical Readiness Training (APRT)
Number of subjects: 67
Study 20158298 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CACR)
Number of subjects: 160
Study 20158298 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (CATT)
Number of subjects: 160
Study 19226890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus Ligustrazine
Number of subjects: 86
Study 19226890 — intervention group
Group type: COMPARATOR
Intervention: Ligustrazine
Number of subjects: 86
Study 16213325 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-based treatment (n = 73)
Number of subjects: 155
Study 16213325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based treatment (n = 47)
Number of subjects: 155
Study 16213325 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from CsA to tacrolimus (n = 35)
Number of subjects: 155
Study 11947912 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 58
Study 11947912 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 58
Study 11370581 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25 (Monocryl) used in 136 cases
Number of subjects: 178
Study 11370581 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomer 631 (Biosyn) used in 116 cases
Number of subjects: 178
Study 8574272 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI D7114 (150 mg/day)
Number of subjects: 16
Study 8574272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2301986 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial food colours
Number of subjects: 19
Study 2301986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31694653 — intervention group
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller® (LMC) system with serious games for upper limb rehabilitation (n=12)
Number of subjects: 23
Study 31694653 — intervention group
Group type: COMPARATOR
Intervention: Specific intervention for upper limb rehabilitation (n=11)
Number of subjects: 23
Study 28196486 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care at home (additional home evaluation by a community geriatrics unit with access to a call service and coordinated follow-up)
Number of subjects: 301
Study 28196486 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care at home
Number of subjects: 301
Study 28196486 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 301
Study 26095227 — intervention group
Group type: EXPERIMENTAL
Intervention: Body checking behaviour
Number of subjects: 55
Study 26095227 — intervention group
Group type: COMPARATOR
Intervention: Control condition (randomized computer-emitted acoustic signals)
Number of subjects: 55
Study 23677386 — intervention group
Group type: EXPERIMENTAL
Intervention: In SHAPE program (one year of weekly sessions with a fitness trainer plus a fitness club membership)
Number of subjects: 133
Study 23677386 — intervention group
Group type: COMPARATOR
Intervention: Fitness club membership and education (control)
Number of subjects: 133
Study 20815720 — intervention group
Group type: EXPERIMENTAL
Intervention: Early soft palate repair in infants with unilateral cleft lip and palate (UCLP)
Number of subjects: 41
Study 20815720 — intervention group
Group type: COMPARATOR
Intervention: Control group (typically developing children without clefts)
Number of subjects: 41
Study 19264687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg administered in five monthly infusions)
Number of subjects: 20
Study 19264687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19264687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 20
Study 17889778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime treatment
Number of subjects: 0
Study 17889778 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15466264 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123
Number of subjects: 6
Study 15466264 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 + E (enalapril)
Number of subjects: 6
Study 11575287 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-brain stimulation of the subthalamic nucleus
Number of subjects: 134
Study 11575287 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-brain stimulation of the pars interna of the globus pallidus
Number of subjects: 134
Study 9643742 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (2 IU daily)
Number of subjects: 50
Study 9643742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9643742 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 50
Study 7838582 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 146
Study 7838582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive self-hypnosis training (CSH)
Number of subjects: 146
Study 7838582 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 146
Study 7838582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hypnotizable subjects (AT or CSH)
Number of subjects: 146
Study 7838582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-hypnotizable subjects (AT or CSH)
Number of subjects: 146
Study 3169118 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine (1.2 g daily)
Number of subjects: 8
Study 3169118 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (0.3 g daily)
Number of subjects: 8
Study 3169118 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 29782479 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent balance and resistance training intervention (once weekly supervised group sessions with home sessions encouraged twice weekly)
Number of subjects: 33
Study 29782479 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent balance and resistance training intervention
Number of subjects: 33
Study 29920171 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC)
Number of subjects: 34
Study 29920171 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of LARC
Number of subjects: 34
Study 29920171 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about insertion and removal of LARC
Number of subjects: 34
Study 29920171 — intervention group
Group type: EXPERIMENTAL
Intervention: Affordability of LARC
Number of subjects: 34
Study 29920171 — intervention group
Group type: EXPERIMENTAL
Intervention: Regret from trying LARC
Number of subjects: 34
Study 28096020 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program (PEP)
Number of subjects: 70
Study 28096020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 25249313 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 52
Study 25249313 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DOTA (0.1 mmol/kg BW)
Number of subjects: 52
Study 23811645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerasorb(®)
Number of subjects: 10
Study 23811645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerasorb(®) and BioMend Extend™
Number of subjects: 10
Study 21876061 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg micafungin
Number of subjects: 36
Study 21876061 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg micafungin
Number of subjects: 36
Study 21876061 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (both doses)
Number of subjects: 36
Study 18053051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-hydroxy acid (30% glycolic acid)
Number of subjects: 20
Study 18053051 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-hydroxy acid (30% salicylic acid)
Number of subjects: 20
Study 16414419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunny Days, Healthy Ways curriculum
Number of subjects: 2038
Study 12942300 — intervention group
Group type: COMPARATOR
Intervention: 81 kVp (CEC)
Number of subjects: 59
Study 12942300 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 kVp (non-CEC)
Number of subjects: 59
Study 12942300 — intervention group
Group type: COMPARATOR
Intervention: 90 kVp (CEC)
Number of subjects: 59
Study 12942300 — intervention group
Group type: EXPERIMENTAL
Intervention: 102 kVp (non-CEC)
Number of subjects: 59
Study 12942300 — intervention group
Group type: EXPERIMENTAL
Intervention: All kVp values
Number of subjects: 59
Study 10729306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 + 30 IU/ml of hyaluronidase
Number of subjects: 150
Study 10729306 — intervention group
Group type: COMPARATOR
Intervention: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 alone
Number of subjects: 150
Study 9020426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine 0.1%
Number of subjects: 10
Study 9020426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1390305 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (rIFN alfa‐2a)
Number of subjects: 178
Study 1390305 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a + vinblastine (VLB)
Number of subjects: 178
Study 1390305 — intervention group
Group type: COMPARATOR
Intervention: Both treatment arms
Number of subjects: 178
Study 1390305 — intervention group
Group type: COMPARATOR
Intervention: Performance status 0
Number of subjects: 178
Study 1390305 — intervention group
Group type: COMPARATOR
Intervention: Performance status 1
Number of subjects: 178
Study 1390305 — intervention group
Group type: COMPARATOR
Intervention: Performance status 2
Number of subjects: 178
Study 1390305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (rIFN alfa‐2a + VLB)
Number of subjects: 178
Study 1390305 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (rIFN alfa‐2a)
Number of subjects: 178
Study 3902068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase infusion
Number of subjects: 302
Study 3902068 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 302
Study 29595659 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery pressure pulse wave treatment in stroke patients with hemiplegia
Number of subjects: 84
Study 29595659 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 matched patients)
Number of subjects: 84
Study 29081178 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management guidance and adjusted diuretic drugs regimen based on body weight changes
Number of subjects: 350
Study 29081178 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care post discharge (Control)
Number of subjects: 350
Study 26314275 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg fortnightly after induction)
Number of subjects: 101
Study 26314275 — intervention group
Group type: COMPARATOR
Intervention: Thiopurines (azathioprine 2 mg/kg/day or mercaptopurine 1.5 mg/kg/day)
Number of subjects: 101
Study 23216710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux thromboprophylaxis
Number of subjects: 92
Study 23216710 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) thromboprophylaxis
Number of subjects: 92
Study 23216710 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong IgG antibodies (≥ 1.0 OD units and ≥ 2× baseline)
Number of subjects: 92
Study 23216710 — intervention group
Group type: COMPARATOR
Intervention: No strong IgG antibodies
Number of subjects: 92
Study 23216710 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anti-PF4/heparin IgG responses
Number of subjects: 92
Study 21624100 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (0.4 μg min m(‐2))
Number of subjects: 7
Study 21624100 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 18945995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet and low-dose vitamin D (Cinacalcet-D)
Number of subjects: 173
Study 18945995 — intervention group
Group type: COMPARATOR
Intervention: Flexible vitamin D alone (Flex-D)
Number of subjects: 173
Study 16467100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg plus sirolimus 5 mg (not on EIAEDs)
Number of subjects: 34
Study 16467100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 1000 mg plus sirolimus 10 mg (on EIAEDs)
Number of subjects: 34
Study 14734876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RTUF) for 12 weeks
Number of subjects: 61
Study 14734876 — intervention group
Group type: COMPARATOR
Intervention: Maize and soy flour for 12 weeks
Number of subjects: 61
Study 11314676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cocaine (100 mg/70 kg)
Number of subjects: 9
Study 9312761 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Hypertension (HT)
Number of subjects: 108
Study 8287998 — intervention group
Group type: EXPERIMENTAL
Intervention: sectoral, scatter laser photocoagulation
Number of subjects: 88
Study 8287998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 88
Study 3809244 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (4 tablets of 500 mg/day for 14 days)
Number of subjects: 60
Study 3809244 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine (4 tablets of 500 mg/day for 14 days)
Number of subjects: 60
Study 3809244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 placebo tablets/day for 14 days)
Number of subjects: 60
Study 31302695 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (i.v. every 4 weeks plus standard therapy)
Number of subjects: 738